BR112014025840A2 - 6-amino-nicotinamidas substituídas tendo um grupo contendo oh como moduladores de kcnq2/3. - Google Patents

6-amino-nicotinamidas substituídas tendo um grupo contendo oh como moduladores de kcnq2/3.

Info

Publication number
BR112014025840A2
BR112014025840A2 BR112014025840A BR112014025840A BR112014025840A2 BR 112014025840 A2 BR112014025840 A2 BR 112014025840A2 BR 112014025840 A BR112014025840 A BR 112014025840A BR 112014025840 A BR112014025840 A BR 112014025840A BR 112014025840 A2 BR112014025840 A2 BR 112014025840A2
Authority
BR
Brazil
Prior art keywords
kcnq2
modulators
substituted
containing group
nicotinamides
Prior art date
Application number
BR112014025840A
Other languages
English (en)
Portuguese (pt)
Inventor
Gregor Bahrenberg
Achim Kless
Sven Kuhnert
Simon Lucas
Wolfgang Schroder
Original Assignee
Gruenenthal Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gruenenthal Gmbh filed Critical Gruenenthal Gmbh
Publication of BR112014025840A2 publication Critical patent/BR112014025840A2/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5355Non-condensed oxazines and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/10Drugs for disorders of the urinary system of the bladder
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81Amides; Imides
    • C07D213/82Amides; Imides in position 3

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Addiction (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
BR112014025840A 2012-04-18 2013-04-17 6-amino-nicotinamidas substituídas tendo um grupo contendo oh como moduladores de kcnq2/3. BR112014025840A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP12002709 2012-04-18
PCT/EP2013/001134 WO2013156154A1 (en) 2012-04-18 2013-04-17 Substituted 6-amino-nicotinamides bearing an oh-containing group as kcnq2/3 modulators

Publications (1)

Publication Number Publication Date
BR112014025840A2 true BR112014025840A2 (pt) 2017-07-18

Family

ID=48227140

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014025840A BR112014025840A2 (pt) 2012-04-18 2013-04-17 6-amino-nicotinamidas substituídas tendo um grupo contendo oh como moduladores de kcnq2/3.

Country Status (21)

Country Link
EP (1) EP2888233B1 (enExample)
JP (1) JP6033403B2 (enExample)
CN (1) CN104428287A (enExample)
AR (1) AR090739A1 (enExample)
AU (1) AU2013248637A1 (enExample)
BR (1) BR112014025840A2 (enExample)
CA (1) CA2870573A1 (enExample)
CY (1) CY1118255T1 (enExample)
DK (1) DK2888233T3 (enExample)
EA (1) EA201401142A1 (enExample)
ES (1) ES2605947T3 (enExample)
HK (1) HK1210173A1 (enExample)
HR (1) HRP20161424T1 (enExample)
HU (1) HUE030859T2 (enExample)
IL (1) IL235030A0 (enExample)
LT (1) LT2888233T (enExample)
MX (1) MX2014012494A (enExample)
PT (1) PT2888233T (enExample)
RS (1) RS55466B1 (enExample)
SI (1) SI2888233T1 (enExample)
WO (1) WO2013156154A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112018071654A2 (pt) * 2016-04-22 2019-02-19 Ono Pharmaceutical Co., Ltd. polimorfismo de cristal do ativador de canais kcnq2-5
JP7262468B2 (ja) * 2017-12-29 2023-04-21 スリーエム イノベイティブ プロパティズ カンパニー 熱硬化性2剤型加工用接着剤組成物

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2230392A1 (de) 1972-06-22 1974-01-31 Cassella Farbwerke Mainkur Ag Substituierte pyridinverbindungen und verfahren zu ihrer herstellung
DE2513949A1 (de) 1975-03-29 1976-10-07 Bayer Ag Azofarbstoffe
MXPA03007397A (es) 2001-02-20 2003-12-04 Bristol Myers Squibb Co Moduladores de canales de potasio kcnq y uso de los mismos en tratamiento de migrana y enfermedades mecanicamente relacionadas.
EP1361879A1 (en) * 2001-02-20 2003-11-19 Bristol-Myers Squibb Company 2,4-disubstituted pyrimidine-5-carboxamide derivatives as kcnq potassium channel modulators
EP2086935A1 (de) * 2006-10-16 2009-08-12 Grünenthal GmbH Substituierte sulfonamid-derivate als bradykinin 1 rezeptor modulatoren
DE102006049452A1 (de) 2006-10-17 2008-05-08 Grünenthal GmbH Substituierte Tetrahydropyrolopiperazin-Verbindungen und deren Verwendung in Arzneimitteln
DK2350093T3 (da) 2008-10-24 2012-11-12 Gruenenthal Gmbh Substituerede 4,5,6,7-tetrahydrothienopyridiner som KCNQ2/3-modulatorer til behandling af smerte, epilepsi og urininkontinens.
TWI475020B (zh) * 2009-03-12 2015-03-01 The substituted nicotine amide as a KCNQ2 / 3 modifier
US8552200B2 (en) * 2010-10-20 2013-10-08 Gruenenthal Gmbh Substituted 6-amino-nicotinamides as KCNQ2/3 modulators

Also Published As

Publication number Publication date
JP6033403B2 (ja) 2016-11-30
SI2888233T1 (sl) 2016-12-30
PT2888233T (pt) 2017-01-04
EP2888233A1 (en) 2015-07-01
EP2888233B1 (en) 2016-09-28
HRP20161424T1 (hr) 2016-12-16
CY1118255T1 (el) 2017-06-28
WO2013156154A1 (en) 2013-10-24
ES2605947T3 (es) 2017-03-17
MX2014012494A (es) 2015-01-15
AU2013248637A1 (en) 2014-12-04
EA201401142A1 (ru) 2015-03-31
AR090739A1 (es) 2014-12-03
CA2870573A1 (en) 2013-10-24
JP2015514728A (ja) 2015-05-21
DK2888233T3 (en) 2017-01-09
HUE030859T2 (en) 2017-06-28
LT2888233T (lt) 2017-01-10
IL235030A0 (en) 2014-12-31
CN104428287A (zh) 2015-03-18
HK1210173A1 (en) 2016-04-15
RS55466B1 (sr) 2017-04-28

Similar Documents

Publication Publication Date Title
PT2858269T (pt) Método de comunicação de informações
PL2920363T3 (pl) Układ środka papierniczego, sposób wytwarzania układu środka papierniczego oraz jego zastosowanie
BRPI1008948A2 (pt) nicotinamida substituída como moduladores kcnq2/3.
BR112015000671A2 (pt) sistema de biorrefinaria, métodos e composições dos mesmos.
BR112015002349A2 (pt) sistema de filtragem, e, método de filtração
EP2852202A4 (en) Control node and communication control method
IL282628A (en) Electromagnetic (em) probes, methods of using such em probes and systems which use such electromagnetic em probes
BR112014029884A2 (pt) sistemas de controle e método.
BR112013033811A2 (pt) composição, método de preparação da composição, e, composto
BR302012005339S1 (pt) "configuração aplicada em pote".
CU24158B1 (es) Método de obtención de 1-kestosa
FI20176131L (fi) Menetelmä biopolttoaineen tai
BR112013010957A2 (pt) 6-amino-nicotinamidas substituídas como moduladores kcnq2/3
EP2993838A4 (en) METHOD FOR SETTING THE IDENTITY OF A GATEWAY DEVICE AND MANAGING A GATEWAY DEVICE
BR112015002723A2 (pt) aparelho e método de controle de comunicação.
BR112014032745A2 (pt) novos derivados de piridina fundidas úteis como inibidores da tirosina quinase c-met
BR112016013944A2 (pt) método de fabricação de um catalisador de fcc
EP2829423A4 (en) SUSPENSION DEVICE
EP2934518A4 (en) SPIROCYCLIC CETP INHIBITORS
EP2756423A4 (en) train control system
BR112015009911A2 (pt) aparelho de chuveiro sustentável e método de banho sustentável.
FI20126284A7 (fi) Valvontajärjestelmä ja -menetelmä
DK3049100T3 (da) Modificerede fibroblastvækstfaktorer-1 til behandling af øjenlidelser
BR112015009097A2 (pt) método de controle de um aparelho formador de imagens, e aparelho formador de imagens.
EP2873169A4 (en) DEVICE RECOGNITION AND P2P GROUPS SCHEME

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]